Objective Pharmacological options for patients with a failing systemic right ventricle (RV) in the context of transposition of the great arteries (TGA) after atrial switch or congenitally corrected ...

For the second time in under 3 weeks, the FDA has approved a treatment for the inherited genetic disorder characterized by recurrent episodes of severe swelling.

FDA approves first oral hereditary angioedema (HAE) therapy: Ekterly (sebetralstat) becomes the first and only FDA-approved oral on-demand treatment for HAE attacks in patients 12 and older. Phase III ...

BOSTON, Mass., July 07, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today ...

The antibody-based drug Andembry is the first to target factor XIIa, a protein responsible for swelling in people with this rare genetic disorder.

The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, according to a press release from CSL Behring. The approval was based on ...

By Adriano Marchese KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema.

Pharvaris announced abstract acceptances for the 2025 National Summit on hereditary angioedema, featuring multiple poster presentations on deucrictibant.

CAMBRIDGE, Mass. & SALISBURY, England, July 07, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY ...

--Celldex Therapeutics, Inc. today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’ s Phase 2 clinical trial in chronic spontaneous ...